Relationships between physical and immunological tumor microenvironment in pancreatic ductal adenocarcinoma.
elasticity
immunology
pancreatic neoplasm
pathology
tumor microenvironment
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
26
04
2023
received:
03
02
2023
accepted:
05
05
2023
medline:
5
9
2023
pubmed:
20
6
2023
entrez:
20
6
2023
Statut:
ppublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is physically palpated as a hard tumor with an unfavorable prognosis. Assessing physical features and their association with pathological features could help to elucidate the mechanism of physical abnormalities in cancer tissues. A total of 93 patients who underwent radical surgery for pancreatic and bile duct cancers at a single center hospital during a 28-month period were recruited for this study that aimed to estimate the stiffness of PDAC tissues compared to the other neoplasms and assess relationships between tumor stiffness and pathological features. Physical alterations and pathological features of PDAC, with or without preoperative therapy, were analyzed. The immunological tumor microenvironment was evaluated using multiplexed fluorescent immunohistochemistry. The stiffness of PDAC correlated with the ratio of Azan-Mallory staining, α-smooth muscle actin, and collagen I-positive areas of the tumors. Densities of CD8
Identifiants
pubmed: 37337413
doi: 10.1111/cas.15853
pmc: PMC10475771
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3783-3792Subventions
Organisme : Fund for the Promotion of Joint International Research
ID : 21K
Informations de copyright
© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15101-8
pubmed: 22932871
Neoplasia. 2016 Dec;18(12):732-741
pubmed: 27886639
Trends Cancer. 2018 Apr;4(4):292-319
pubmed: 29606314
Int J Cancer. 2021 Aug 1;149(3):546-560
pubmed: 33662146
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Int J Mol Sci. 2020 Oct 03;21(19):
pubmed: 33022971
Cancers (Basel). 2022 Feb 16;14(4):
pubmed: 35205742
Cancer Sci. 2023 Sep;114(9):3783-3792
pubmed: 37337413
Sci Rep. 2020 Oct 26;10(1):18278
pubmed: 33106543
J Exp Med. 1900 Oct 1;5(1):15-20
pubmed: 19866932
Surgery. 2014 Nov;156(5):1204-11
pubmed: 25444318
Gut. 2004 Apr;53(4):581-6
pubmed: 15016755
Int J Cancer. 2020 Feb 15;146(4):895-905
pubmed: 30734283
Science. 2009 Jun 12;324(5933):1457-61
pubmed: 19460966
Science. 2020 Oct 30;370(6516):
pubmed: 33122355
Sci Rep. 2018 Sep 3;8(1):13166
pubmed: 30177687
J Clin Oncol. 2013 Jun 10;31(17):2205-18
pubmed: 23669226
Cancer Sci. 2018 Jul;109(7):2085-2092
pubmed: 29737600
Front Cell Dev Biol. 2021 Nov 25;9:787485
pubmed: 34901028
Nat Commun. 2013;4:2516
pubmed: 24084631
Microvasc Res. 2003 Nov;66(3):204-12
pubmed: 14609526
Cancers (Basel). 2014 Oct 21;6(4):2137-54
pubmed: 25337831
Cold Spring Harb Perspect Med. 2016 Dec 1;6(12):
pubmed: 27663981
Cancer Sci. 2015 Sep;106(9):1232-9
pubmed: 26083008
JAMA Oncol. 2019 Jul 01;5(7):1020-1027
pubmed: 31145418
Mod Pathol. 2019 Oct;32(10):1495-1507
pubmed: 31186528
Eur J Radiol. 2018 Jun;103:99-104
pubmed: 29803393
Sci Rep. 2019 Nov 20;9(1):17145
pubmed: 31748528
Cancer Res. 2000 May 1;60(9):2497-503
pubmed: 10811131
Front Oncol. 2021 Jul 14;11:691185
pubmed: 34336679
Oncol Rep. 2022 Jul;48(1):
pubmed: 35583018